Slingshot members are tracking this event:

Bristol-Myers Squibb's (BMY) Phase 3 CheckMate of Opdivo Plus Low-Dose Yervoy in Lung Cancer Patients with High Tumor Mutational Burden Data Presented at AACR

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
Additional data from CheckMate -227 presented at AACR 2018 include subgroup analyses by tumor PD-L1 expression in patients with TMB ≥10 mut/Mb. In these analyses, PFS was significantly improved with the combination versus chemotherapy in patients with PD-L1 ≥1% (HR 0.62; 95% CI: 0.44 to 0.88) and PD-L1 <1% (HR 0.48; 95% CI: 0.27 to 0.85). Increased benefit with Opdivo plus low-dose Yervoyversus chemotherapy was also observed in patients with squamous histology (HR 0.63; 95% CI: 0.39 to 1.04) and non-squamous histology (HR 0.55; 95% CI: 0.38 to 0.80).In the study, PFS also was evaluated with Opdivo versus chemotherapy among patients with TMB ≥13 mut/Mb and ≥1% PD-L1 expression as a secondary endpoint. An improvement in PFS with Opdivo monotherapy was not observed (HR 0.95; 97.5% CI: 0.61 to 1.48; p=0.7776).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 16, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Checkmate, Phase 3 Study, Opdivo, Yervoy, Lung Cancer